Apheresis involves passing a person’s blood through a device that separates one constituent and returns the remainder to circulation. Apheresis is mostly used to extract stem cells. The most popular technique for density separation is centrifugation. Other techniques involve coating the beads with an absorbent substance and filtering them.
In 2021, the apheresis market value was worth USD 1.79 billion, and by 2030 it will be worth USD 3.87 billion, growing at a 7.78% CAGR during the forecast period.
The apheresis market is expanding due to rising blood cancer rates among people. Other factors boosting market expansion include the increasing use of apheresis procedures in treating illnesses like hematological, cardiology, and autoimmune conditions, as well as the rising demand for plasma from the biopharmaceuticals sector.
Market Dynamics
Drivers
The growth of numerous chronic diseases and blood-related illnesses, as well as the increased need for source plasma from biopharmaceutical companies, are some of the factors driving the apheresis market size. The market has grown due to an increase in the demand for various blood components, the complexity of surgical procedures, and an increase in accidents around the world. The most recent authorized novel apheresis indications are neonatal cardiac lupus, autoimmune hemolytic anemia, and acute disseminated encephalomyelitis. According to the National Health Service (NHS) Blood and Transplant, there is a growing demand for platelets, which will boost the market share for apheresis during the projection period.
Restraints
The Apheresis Market Value is declining as a result of the market’s poor growth, a lack of skilled specialists, and the ease with which blood and blood products might contract infections. However, a number of issues, including the high cost of apheresis machines and therapeutic apheresis treatments, installation of apheresis units using the rental model, and fewer blood donations utilizing apheresis due to lack of awareness, will restrain market expansion.
Opportunity
An increase in demand for plasma-derived medicines presents significant prospects for market expansion. Furthermore, the rise in the prevalence of chronic diseases, the rise in surgical procedures, and the rise in accidents and injuries are all driving the market’s expansion.
Market Segmentation
By Product
On the basis of product, the market is segmented into software, apheresis devices, and disposable & reagents.
The disposables and reagents segment led the entire market with a significant revenue share in 2020. Furthermore, the centrifugal apheresis segment will expand rapidly during the forecast period. It is due to the benefits of centrifugation over other methods and its ability to distinguish various kinds of blood components.
By Application
In 2022, plasmapheresis led the market with the largest revenue share of 53.3%. Patients with compromised immune systems get plasma-based drugs in an effort to increase their resistance to infection and disease. The market will expand as the prevalence of blood-related disorders increases and the demand for medicines generated from plasma rises.
Throughout the projection period, the leukapheresis segment will have profitable expansion. During the projected period, utilization rates will increase due to rising cancer incidence rates, particularly leukemia, breast, and prostate cancer.
By Technology
The centrifugation devices segment ruled the market with 57% of the revenue share in 2022. As a result of its increased usage rates, centrifugation produces outcomes that are simpler, quicker, and more accurate than membrane filtering. Also, the segment will rise due to the rising demand for automated apheresis systems. To increase product efficiency, businesses are developing technologically sophisticated and automated systems. The makers are creating automated interface systems, customized anticoagulant infusion systems, and automatic apheresis equipment with continuous flow centrifugation.
Regional Overview
In 2022, North America dominated the global market with a revenue share of 35.2%. The main drivers of the market in North America are the rising prevalence of blood-related ailments such as kidney disease, metabolic disease, cancer, and neurological disorders, the rising number of donors, and the demand for blood components. The American National Red Cross estimates that about 6.8 million Americans donate blood annually.
On the other hand, the Asia Pacific will experience rapid growth. It is due to the rising incidence of blood illnesses needing plasma and platelet transfusions in developing nations like China and India.
Key Players
- Asahi Kasei Medical
- Terumo BCT
- Haemonetics Corporation
- Kaneka Corporation
- Kawasumi Laboratories
- HemaCare Corporation
- Cerus Corporation
- Braun Melsungen AG
- Nikkiso
- Fresenius Kabi
In 2021, the apheresis market value was worth USD 1.79 billion, and by 2030 it will be worth USD 3.87 billion, growing at a 7.78% CAGR during the forecast period. The market expansion will be driven by the increased prevalence of blood-related illnesses. The availability of supportive government initiatives, and reimbursement frameworks. Additionally, the demand for apheresis equipment will be supported by the increased popularity. And involvement in blood donation drives and camps and the rising number of blood transfusions.
Related Reports:
Industrial Air Compressor Market Report – The global industrial air compressor market will witness a robust CAGR of 3.9%, valued at $32.42 billion in 2021, expected to appreciate and reach $43.75 billion by 2030, confirms Strategic Market Research. An industrial air compressor is a tool that transforms power into potential energy stored in pressured air using either a gasoline-powered engine or an electric motor or diesel.